See also this year's filing and all EDGAR filings for this company.
PDF Report 0001269021_2019_PORTOLA_PHARMACEUTICALS_INC.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Liabilities', 'missing_ratio': 0.011000126438234923, 'aggregate_val': 295852000, 'exp_sum': 292633000, 'exp_to_value': {'LiabilitiesCurrent': 69005000, 'LiabilitiesNoncurrent': 168449000, 'remainder_Liabilities': 55179000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001269021')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001269021, PORTOLA PHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 353,327,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 7,279,000 |
| 2 | PropertyPlantAndEquipmentNet | 5,236,000 |
| 3 | remainder_Assets | 20,577,000 |
| 4 | LiabilitiesCurrent | 69,005,000 |
| 5 | LiabilitiesNoncurrent | 168,449,000 |
| 6 | remainder_Liabilities | 58,398,000 |
| 7 | CostOfGoodsAndServicesSold | 18,081,000 |
| 8 | SellingGeneralAndAdministrativeExpense | 151,164,000 |
| 9 | ResearchAndDevelopmentExpense | 216,205,000 |
| 10 | remainder_Expenses | 18,740,000 |
| 11 | remainder_Revenues | 40,130,000 |
| 12 | remainder_NetIncome | 13,516,000 |
| 13 | remainder_ComprehensiveNetIncome | 447,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 386,419,000 |
| 1 | Liabilities | 295,852,000 |
| 2 | Expenses | 404,190,000 |
| 3 | Revenues | 40,130,000 |
| 4 | StockholdersEquity | 90,567,000 |
| 5 | NetIncome | -350,544,000 |
| 6 | ComprehensiveNetIncome | -350,320,500 |
| 7 | BaseVar | 570,277,000 |
| 8 | EconomicCapitalRatio | -0.570 |
Edgar->Model Mapping
Feature Distribution
Change over Time
